• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Cencora Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    9/3/25 4:43:27 PM ET
    $COR
    Other Pharmaceuticals
    Health Care
    Get the next $COR alert in real time by email
    false 0001140859 0001140859 2025-09-03 2025-09-03 0001140859 us-gaap:CommonStockMember 2025-09-03 2025-09-03 0001140859 COR:Sec2.875SeniorNotesDue2028Member 2025-09-03 2025-09-03 0001140859 COR:Sec3.625SeniorNotesDue2032Member 2025-09-03 2025-09-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): September 3, 2025

     

     

     

    Cencora, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Commission File Number: 1-16671

     

    Delaware   23-3079390
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)

     

    1 West First Avenue
    Conshohocken, PA
      19428-1800
    (Address of principal executive offices)   (Zip Code)

     

    (610) 727-7000

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report.)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of exchange on which registered
    Common Stock COR New York Stock Exchange (NYSE)
    2.875% Senior Notes due 2028 COR28 New York Stock Exchange (NYSE)
    3.625% Senior Notes due 2032 COR32 New York Stock Exchange (NYSE)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 8.01 Other Events.

     

    On September 3, 2025, Cencora, Inc., a Delaware corporation (the “Company”), announced an agreement, subject to court approval, that would resolve the stockholder derivative action captioned Lebanon County Employees’ Retirement Fund v. Steven H. Collis et al., C.A. No. 2021-1118-JTL (the “Action”).

     

    As the Company has previously disclosed, on December 30, 2021, the Lebanon County Employees’ Retirement Fund and Teamsters Local 443 Health Services & Insurance Plan (the “Plaintiffs”) filed a complaint for the Action in the Court of Chancery of the State of Delaware (the “Court”) against the Company and certain of its officers and members of its Board of Directors (the “Board”). The complaint alleges claims for breach of fiduciary duty allegedly arising from the Board’s and certain officers’ oversight of the Company’s controlled substance diversion control programs. On January 12, 2024, the Board established a Special Litigation Committee (the “SLC”) and delegated to the SLC the Board’s full authority with respect to the litigation. On March 4, 2024, the Court granted the SLC’s consented-to motion to stay the Action pending its investigation of the allegations within the complaint. On July 28, 2025, the SLC notified the Court that the parties had reached an agreement in principle to settle all claims in the Action following a successful mediation conducted on June 24, 2025, and filed a stipulation to stay the Action pending the presentation of a stipulation of settlement for the Court's approval. The Court granted the stipulation staying the Action on July 29, 2025.

     

    On August 15, 2025, the parties to the Action filed a Stipulation and Agreement of Settlement, Compromise, and Release to the Court (the “Stipulation”) that would resolve the Action. If the Court approves the Stipulation, insurance carriers would pay the Company $111.3 million, less any attorneys’ fees and litigation expenses awarded by the Court to Plaintiffs’ counsel. The Stipulation does not include any admission of liability, and the defendants expressly deny any wrongdoing.

     

    On August 19, 2025, the Court entered a Scheduling Order in the Action directing the Company (i) to file this Current Report on Form 8-K with the Securities and Exchange Commission with copies of the Stipulation and the Notice of Pendency and Proposed Settlement of Stockholder Derivative Action, Settlement Hearing, and Right to Appear (the “Notice”) filed as exhibits hereto, and (ii) to post a copy of the Stipulation and the Notice on the “Investor Relations” section of the Company’s website.

     

    Copies of the Stipulation and the Notice are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference. The Stipulation and the Notice are also available on the Investor Relations section of the Company’s website at https://investor.cencora.com.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d)         Exhibits.

     

    Exhibit No.

     

    Description

    99.1   Stipulation and Agreement of Settlement, Compromise, and Release
    99.2   Notice of Pendency and Proposed Settlement of Stockholder Derivative Action, Settlement Hearing, and Right to Appear
    104   Cover Page Interactive Data File (formatted as inline XBRL)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Cencora, Inc.
         
         
    September 3, 2025 By: /s/ Elizabeth S. Campbell
        Name: Elizabeth S. Campbell
        Title: Executive Vice President and Chief Legal Officer

     

     

    Get the next $COR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COR

    DatePrice TargetRatingAnalyst
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    12/14/2023$213.00Equal Weight
    Wells Fargo
    12/14/2021$162.00 → $170.00Buy → Neutral
    Citigroup
    11/26/2021$136.00 → $170.00Sector Perform
    RBC Capital
    More analyst ratings

    $COR
    SEC Filings

    View All

    Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    9/9/25 5:00:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    9/3/25 4:43:27 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    8/27/25 5:00:50 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

    Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, effective October 1, 2025. Mr. Durcan will succeed Steven H. Collis, who has served as Cencora's Chairman since 2016 and previously served as Cencora's Chief Executive Officer from 2011 until 2024. As previously disclosed, Mr. Collis was elected to serve as Executive Chairman of the Board effective October 1, 2024 for a period of one year. "Our Board is confident that Mark's public company CEO and board experience, along with his strategic planning and technological innovation experience, make him the right person to step into t

    8/27/25 4:15:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Reports Fiscal 2025 Third Quarter Results

    Revenue of $80.7 billion for the Third Quarter, an 8.7 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.52 and Adjusted Diluted EPS of $4.00 Adjusted Diluted EPS Guidance Range Raised to $15.85 to $16.00 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.52 for the third quarter of fiscal 2025 compared to $2.42 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below

    8/6/25 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 6, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the c

    7/3/25 7:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Collis Steven H exercised 12,579 shares at a strike of $86.09 and sold $4,227,618 worth of shares (14,579 units at $289.98), decreasing direct ownership by 0.65% to 307,913 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    8/20/25 4:08:31 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    President & CEO Mauch Robert P. exercised 3,225 shares at a strike of $86.09 and sold $1,458,257 worth of shares (4,968 units at $293.53), decreasing direct ownership by 4% to 40,608 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    8/20/25 4:06:37 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Director Nally Dennis M was granted 122 shares, increasing direct ownership by 0.92% to 13,373 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    8/4/25 4:33:42 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $COR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    5/29/24 4:02:27 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Cencora from Equal Weight to Overweight and set a new price target of $337.00

    6/3/25 7:24:57 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Mizuho resumed coverage on Cencora with a new price target

    Mizuho resumed coverage of Cencora with a rating of Outperform and set a new price target of $280.00

    12/4/24 7:30:44 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora downgraded by BofA Securities with a new price target

    BofA Securities downgraded Cencora from Buy to Neutral and set a new price target of $245.00 from $275.00 previously

    9/18/24 8:27:47 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Financials

    Live finance-specific insights

    View All

    Cencora Reports Fiscal 2025 Third Quarter Results

    Revenue of $80.7 billion for the Third Quarter, an 8.7 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.52 and Adjusted Diluted EPS of $4.00 Adjusted Diluted EPS Guidance Range Raised to $15.85 to $16.00 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.52 for the third quarter of fiscal 2025 compared to $2.42 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below

    8/6/25 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 6, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the c

    7/3/25 7:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Reports Fiscal 2025 Second Quarter Results

    Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

    5/7/25 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    Leadership Updates

    Live Leadership Updates

    View All

    Cencora Appoints Mark Durcan as Chairman of Its Board of Directors

    Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors, effective October 1, 2025. Mr. Durcan will succeed Steven H. Collis, who has served as Cencora's Chairman since 2016 and previously served as Cencora's Chief Executive Officer from 2011 until 2024. As previously disclosed, Mr. Collis was elected to serve as Executive Chairman of the Board effective October 1, 2024 for a period of one year. "Our Board is confident that Mark's public company CEO and board experience, along with his strategic planning and technological innovation experience, make him the right person to step into t

    8/27/25 4:15:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Expands Enterprise Leadership Team with Two Senior Appointments

    Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

    11/4/24 8:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Network Wireless Solutions (NWS) Appoints Michael Millegan to Board of Directors

    The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo

    9/14/21 2:00:00 PM ET
    $AXS
    $COR
    $POR
    Property-Casualty Insurers
    Finance
    Other Pharmaceuticals
    Health Care

    $COR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cencora Inc.

    SC 13G/A - Cencora, Inc. (0001140859) (Subject)

    11/14/24 1:22:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by Cencora Inc.

    SC 13D/A - Cencora, Inc. (0001140859) (Subject)

    8/5/24 6:43:49 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G/A filed by CoreSite Realty Corporation (Amendment)

    SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)

    7/12/21 8:29:18 AM ET
    $COR
    Other Pharmaceuticals
    Health Care